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Abstract
Chronic heart failure (CHF) is a complex clinical syndrome characterized by progressive course, unsatisfactory quality of 
life, poor prognosis and high incidence of concomitant renal dysfunction (RD).
The aim of our work was to study the prognostic value of a number of renal function indicators in patients with CHF and a 
reduced left ventricular ejection fraction (LVEF).
Materials and methods. 134 patients with stable CHF and reduced (<40 %) LVEF, II-IVNYHA class were examined. 
Patients were divided into two groups according to the level of GFR: the first group of GFR<60 ml/min./1.73 m², the second – 
GFR≥60 ml/min./1.73 m². The average follow-up period was 13.4 months, the maximum was 27.5 months.
Results. In 53 patients RD was detected (glomerular filtration rate was ˂60 ml/min/1.73 m²), which was 39.5 %. Patients of 
both groups did not differ in their main hemodynamic parameters, left ventricular ejection fraction, and pharmacotherapy structure, 
but were older in age and heavier clinically. After the analysis of survival curves of patients depending on GFR, a group of patients 
with RD had a significantly worse survival prognosis compared to a group without RD. After adjusting the groups by age and NYHA 
class, the indicated difference was maintained. The subjects were divided according to median levels: blood urea nitrogen, blood urea 
nitrogen/creatinine ratio, microalbuminuria, albumin / creatinine ratio in urine.
The long-term survival of the formed groups was analyzed. The level of blood urea nitrogen did not significantly influence the 
prognosis of patients with CHF and reduced LVEF. At the same time, when the groups were divided, depending on the median value of 
the blood urea nitrogen/creatinine ratio, there was a significantly higher risk of fatal outcome in the group with lower indices. The level 
of MAU did not significantly affect the survival of patients. In addition, a comparison of the survival of patients with higher and lower 
values of the albumin/creatinine ratio in the urine revealed a significantly higher risk of death in patients with higher values.
Conclusions:
1. The presence of RD (GFR˂60 ml/min/1.73 m²) is observed in 39.5 % of patients with CHF and reduced LVEF and is asso-
ciated with their worst long-term survival.
2. The BUN and MAU do not have sufficient predictive information about the forecast of long-term survival of the above 
category of patients.
3. At the same time, the values of the BUN/ Сreatinine ratio ˂24.5 and the ACR˃12.7 indicate patients with CHF who have 
a higher long-term risk of death.
Keywords: chronic heart failure, reduced left ventricular ejection fraction, glomerular filtration rate, blood urea nitrogen, 
microalbuminuria.
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Chronic heart failure (CHF) is a complex clinical syndrome, characterized by a progressive 
course, unsatisfactory quality of life and a worse prognosis [1, 2]. The risk of death within one year 
in patients with CHF, even with modern methods of their treatment, is from 6.9 to 15.6 % according 
to different data [3]. CHF is characterized by a high incidence of concomitant pathology, among 
which renal dysfunction (RD) occupies one of the leading positions.
According to the results of various studies, the number of patients with CHF and RD varies 
from 32 to 66 % [4, 5]. The combination of cardiac and renal pathology is considered within the 
cardio-renal syndrome [6] and is discussed in the context of common factors of pathogenesis and 
mutual influence on the course of CHF, drug therapy, and a prognosis [7]. The glomerular filtra-
tion rate (GFR) is a universal marker for assessing renal function, with a decrease of GFR below 
60 ml/min/1.73 m2 being considered as the presence of RD [8]. It is known that a decrease of GFR 
in patients with CHF has a greater prognostic value than of the left ventricle ejection fraction 
(LVEF) [9]. One of the most important parameters of the renal function is blood urea nitrogen 
(BUN), which, according to a number of researchers, can serve as an indirect marker of neurohu-
moral activation [10]. Non-ligand diagnostic markers of kidney condition include microalbumin-
uria (MAU), and albumin/creatinine ratio (ACR), which makes it possible to level the variability 
of albumin excretion fluctuations due to drinking regimen and hydration [11]. MAU is a proven 
independent predictor of cardiovascular complications in patients with hypertension [12], but data 
on its prognostic value with stable CHF are almost absent.
2. Aim of the research
Taking into account the above, and taking into account the expediency of searching for new 
markers that can help improve the quality of dispensary observation of such patients, the aim of 
our work was to study the prognostic value of a number of renal function indicators in patients with 
CHF and reduced left ventricular ejection fraction (LVEF).
3. Materials and methods
Patients were observed on the basis of the heart failure department in National Scientific 
Center “M.D. Strazhesko Institute of Cardiology” from 2016 to 2018.
134 patients with stable CHF and <40 % LVEF, NYHA class II–IV, whose median age was 
59.5 (54; 68) years were examined. The criteria for inclusion in the study were:
1) the age of patients from 18 to 75 years; 
2) CHF caused by ischemic heart disease (including in combination with AH) or dilated 
cardiomyopathy; 
3) LVEF <40 %; 
4) II–IV functional class according to the criteria of the New York Heart Association 
(NYHA).
The criteria for exclusion were: 
1) age over 75 years; 
2) LVEF>40 %; 
3) GFR≤30 ml/min./1.73 m²; 
4) acute forms of ischemic heart disease; 
5) signs of congestion; 
6) acute infectious diseases; 
7) acute and chronic diseases of the urinary tract and chronic organic kidney damage (glo-
merulonephritis, pyelonephritis), nephrotic syndrome; 
8) unsatisfactory adherence to treatment;
9) diabetes mellitus type I; 
10) acquired valvular heart disease; 
11) inflammatory and restrictive lesions of the myocardium; 
12) oncology; 
13) acute disorders of cerebral circulation; 
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14) availability of artificial pacemakers, cardio-resynchronizing therapy; 
15) severe anemia (Hb<80 g/l).
All patients underwent general clinical examination, routine 12-lead ECG and ultrasound 
examination of the heart by a standard procedure. The creatinine concentration was determined 
by the kinetic method of Jaffe without deproteinization, the level of GFR was estimated using the 
CKD-EPI equation [8]. Determination of the urea concentration was carried out by the urease 
method, the appropriate recalculation factor was used to determine urea nitrogen: urea (mmol/l)× 
×0.467=blood urea nitrogen (mmol/l) [13]. The determination of MAU was carried out using the 
turbidimetric method [14]. The MAU criteria is 29–300 mg of protein in urine per day.
The patients were treated with standard inhibitors of the renin-aldosterone system (RAS), 
diuretics, beta-blockers and antagonists of mineralocorticoid receptors (AMR) in accordance with 
the current standards of the Association of Cardiologists of Ukraine for the diagnosis and treat-
ment of chronic heart failure [15]. Statistical processing of information was carried out using the 
“STATISTICA” software package v. 6.0. Absolute and relative frequencies (n, %) were used to 
describe the qualitative characteristics, for the quantitative indices – the median, upper and lower 
quartiles. The reliability of the differences in the parameters was verified using the Mann-Whitney 
test, for qualitative ones, using the Pearson χ² criterion, with the construction of conjugacy tables. 
The difference was considered reliable at a value of p<0.05. To find the connection between the 
phenomena, the Spearman rank correlation coefficient was used. To evaluate the survival rate, a log 
rank test was used to construct the Kaplan-Meier curves.
5. Results
Patients included in the study in stable CHF with a reduced LVEF were divided into two 
groups according to the level of GFR: the first group of GFR<60 ml/min/1.73 m², the second – 
GFR≥60 ml/min/1.73 m². In 53 patients RD was detected, which consisted 39.5 %. At the first stage, 
patients were compared by age, NYHA class and hemodynamic parameters, and the structure of 
pharmacotherapy, depending on the presence of RD (Table 1). Patients of both groups did not differ 
in hemodynamic parameters such as heart rate (HR), systolic blood pressure (SBP), LVEF and were 
comparable in the structure of the prescribed treatment. At the same time, patients with RD were 
older and characterized, in contrast to patients without RD, by a predominance of higher (III–IV) 
classes according to NYHA (Table 1).
Table 1
Comparability of groups of patients with RD and without RD according to age, indicators of hemodynamics, 
NYHA class and the structure of pharmacotherapy
Indicators GFR<60 ml/min/1.73 m² (n=53)
GFR≥60 ml/min/1.73 m² 
(n=81) Р
Age, (Mе (LQ;UQ) 67 (63; 70) 58 (45;76.4) <0.001
HR, bpm (Mе (LQ;UQ) 76 (70; 82) 72 (66; 80) 0.357
SBP, mm Hg (Mе (LQ;UQ) 110 (100; 120) 110 (110; 120) 0.286
LVEF, % (Mе (LQ;UQ) 26 (21; 33) 29 (22; 35) 0.443
NYHA II (n, %) 9 20 % 36 80 % <0.010
NYHA III–IV (n, %) 44 83 % 45 56 % 0.009
Diuretics (and) (n, %) 51 96 % 76 93 % 0.541
ACE inhibitors or ARB ІІ (n, %) 26 49 % 51 63 % 0.111
BB (n, %) 45 85 % 72 90 % 0.376
AMR (n, %) 42 79 % 70 87 % 0.272
Notes: HR – heart rate; SBP – systolic blood pressure; LVEF – left ventricular ejection fraction; NYHA – New York Heart As-
sociation; ACE inhibitors – angiotensin-converting-enzyme inhibitor; ARB – angiotensin receptor blocker; BB – beta-blockers; 
AMR – antagonists of mineralocorticoid receptors
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We compared and analyzed the survival curves of patients depending on the above-men-
tioned indicators of kidney function. The average follow-up period was 13.4 months, the maximum 
was 27.5 months.
It turned out that a group of patients with RD had a significantly worse survival prognosis 
compared to a group without RD (Fig. 1). After adjusting the groups by age and the NYHA class, 
the difference was maintained (Fig. 2).
Fig. 1. Survival curves of patients with CHF and reduced LVEF depending on the level of GFR, 
n=134; p=0.00065; group 0 – GFR<60 ml/min/1.73 m²; group 1 – GFR≥60 ml/min/1.73 m²
Fig. 2. Survival curves of groups of patients with CHF and reduced LVEF with and without RD, 
age-adjusted and NYHA class, n=99, p=0.014, adjusted; group 0 – GFR<60 ml/min/1.73 m², 
group 1 – GFR≥60 ml/min/1.73 m²
The groups of patients were formed depending on the median of BUN, the BUN/creatinine 
ratio, MAU, the albumin to creatinine ratio (ACR) to assess the prognostic value these indicators. 
It was found that the level of BUN did not significantly affect the prognosis of patients with CHF 
and reduced LVEF (Fig. 3).
At the same time, when the groups were divided, depending on the median value of the 
BUN/creatinine ratio, a significantly higher risk of fatal outcome was observed in the group with 
lower indices (Fig. 4).
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Fig. 3. Survival curves of patients with CHF and reduced LVEF, depending on the median plasma 
level of BUN, n=134, p=0.176; group 1 – BUN level 2.5 mmol/l; group 0 – BUN level <2.5 mmol/l
Fig. 4. Survival curves of patients with CHF and reduced LVEF, depending on the median of 
BUN/creatinine ratio in plasma, n=134, p=0.0009, group 1 – ratio of BUN/creatinine ratio in 
plasma ≥24.5; group 0 – ratio of BUN/creatinine ratio in plasma <24.5
Among the examined MAU patients (29-300 mg/day) occurred in 94 % of cases. The level 
of MAU did not significantly affect their survival (Fig. 5).
Fig. 5. Survival curves of patients with CHF and reduced LVEF, depending on the median of the MAU 
level, n=127; p=0.147; group 1 – level of MAU>104 mg/day; group 0 – level of MAU<104 mg/day
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In addition, a comparison of the survival of patients with higher and lower ACR revealed a 
significantly higher risk of death in patients with higher values (Fig. 6).
Fig. 6. Survival curves of patients with CHF and reduced LVEF, depending on the median of 
ACR, n=134; p=0.028; group 1 – ACR≥12.72 mg/mmol, group 0 – ACR <12.72 mg/mmol
5. Discussion
The study confirmed, on the one hand, the high prevalence (almost 40 %) among patients 
with CHF and reduced LVEF, and on the other hand, the high prognostic significance of low 
GFR˂60 ml/min/1.73 m² in this category of patients [4, 16].
At the same time, we were not able to confirm the prognostic significance of BUN for long-
term survival of such patients [17]. Nevertheless, the analysis of the BUN / creatinine ratio demon-
strated its corresponding high informative value [18]. It is known that both BUN and creatinine 
are freely filtered in the glomerulus of the kidneys, while a part of BUN is reabsorbed under the 
action of vasopressin through the V2 receptors in the proximal tubules [10]. Thus, BUN reflects not 
only the function of glomeruls and tubules, but indirectly indicates the severity of neurohumoral 
activation, which in patients with CHF is most pronounced in a state of decompensation [19, 20]. 
Our patients had standard therapy with neurohumoral antagonists and were in the euvolemic state, 
which may explain the insufficient prognostic information level of BUN as such. An increase in the 
predictive informative value of the last indicator of such a component, which reflects the filtration 
status of the kidneys in the form of BUN / creatinine ratio, allowed to statistically reliably separate 
patients with the worst and best prognosis, which indicates the expediency of further study of this 
marker with stable CHF.
The study showed an almost total (94 %) prevalence of MAU in the surveyed, which is higher 
than that found in a similar category of patients by other authors [21, 22]. The explanation for the dis-
crepancy may be the high prevalence of hypertension and diabetes mellitus (83 % and 42 %, respec-
tively) among our patients. It is known that the presence of MAU displays an increase in the permea-
bility of the glomerular membrane due to its damage by increased hemodynamic load and endothelial 
dysfunction [23]. Nevertheless, the trend toward a higher risk of death in a group of patients with large 
MAU values has not been statistically confirmed. However, the approach that allows to compare the 
levels of albumin and creatinine excreted in the urine was more informative about the stratification of 
the long-term risk of death, which requires confirmation by further studies.
7. Conclusions
1. The presence of RD (GFR˂60 ml/min/1.73 m²) is observed in 39.5 % of patients with CHF 
and reduced LVEF and is associated with their worst long-term survival.
2. Levels of BUN and MAU do not have sufficient predictive information about the forecast 
of long-term survival of the above category of patients.
3. At the same time, the values of the BUN/Creatinine ratio ˂24.5 and the ACR˃12.7 indi-
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Abstract
In recent years surgical treatment of pericardial effusion has been favoured by mini-invasive interventions. Pericardioscopy 
supplements it. In the literature actively discusses its expediency, efficiency and informativeness.
Aim of the study. Analyze our experience of using pericardioscopy during surgical treatment of pericardial effusion using 
mini-invasive interventions.
Materials and methods. From 2000 to 2017, 92 patients with pericardial effusion were operated in our clinic using mini-in-
vasive interventions. Pericardioscopy was used in 72 (78.26 %) cases. In 32 (44.44 %) pericardioscopy was performed with subx-
iphoid pericardiotomy, in 40 (55.56 %) – with thoracoscopy on the right or left side.
Results and discussion. The use of pericardioscopy has allowed to significantly reduce the number of idiopathic pericardi-
tis from 20.0 % to 5.56 % and increase the informativeness of the minimally invasive interventions by 14.44 % (χ2=4.11, with ν=1, 
α=5 %). There is no reliable difference in the number of relapses of the disease.
Conclusions. The use of pericardioscopy during mini-invasive interventions is safe and effective. The method of choice in 
most cases is subxiphoid non-pleural pericardiotomy with pericardioscopy.
Keywords: pericarditis, pericardioscopy, surgical treatment, minimally invasive.
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1. Introduction
In recent years, the incidence of pericarditis has been rising steadily. The reason for this, 
according to many authors, is the development of diagnostic and therapeutic technologies and the 
deterioration of the quality of life of the population [1, 2]. The most common pericardial pathology 
is exudative pericarditis of different etiologies. Cases of the initial occurrence of effusion in the 
pericardium cavity are singular [3, 4]. Their cause in the vast majority are various infectious (viral 
and bacterial), systemic, autoimmune, neoplasm diseases, injuries, heart disease and pericardium, 
etc. [5, 6]. At the same time, to find out the cause of the disease can not always be possible and then 
they speak about the idiopathic nature of the disease [7, 8]. A large number of idiomatic exudative 
pericarditis is an urgent and debatable problem, because without identifying and eliminating the 
root cause, the risk of chronic and recurrent pericardial inflammation is significantly increased 
[1, 9]. The level of mortality from exudative pericarditis depends on many factors, including the eti-
ology, the prescription of the process, the severity of the underlying disease and related disorders, 
